Interventional - Drug
The objective of the TIPS-3 study, is to evaluate a polypill (with and without aspirin) and vitamin D supplementation – compared to their respective placebos – in a primary prevention setting to reduce cardiovascular disease (CVD) outcomes.
It is hypothesized that in individuals without clinical cardiovascular disease, but at increased risk of CVD, a 50 to 60 percent reduction in CVD risk could be achieved using fixed dose combination (FDC) therapy, usually comprised of multiple blood-pressure agents and a statin (with or without aspirin) in a single ‘polypill.’
However, the impact of a polypill in preventing clinical cardiovascular events has not been evaluated, before TIPS-3, in a large randomized controlled trial.
The results of the TIP-3 study will be key to determining the appropriateness of FDC therapy as a strategy in the global prevention of CVD.
Interventional - Drug
Randomized, double-blind, 2x2x2 factorial, placebo controlled
Executive Director; Senior Scientist
Salim Yusuf is an internationally renowned cardiologist and epidemiologist, whose work over 40 years has substantially influenced prevention and treatment of cardiovascular disease. Born in India, medically qualified at St. John’s Medical College, Bangalore in 1976, he received a Rhodes Scholarship and obtained a DPhil from Oxford, during which he (along with Richard Peto, Rory Collins and Peter Sleight) initiated the concepts of large, simple trials, and meta-analysis. He proposed the concept of combination drug treatment for prevention of CVD to achieve large reductions in CVD with a single pill (now called the polypill concept), but more importantly has been evaluating the concept through large randomized trials.
He leads several global studies involving more than 60 countries in every inhabited continent of the world aimed at enhancing knowledge about the biological, behavioural and societal causes, consequences, and approaches to the control of heart diseases, and strokes through large multi-country programs such as INTERHEART, INTERSTROKE, and PURE.
He holds a Heart and Stroke Foundation of Ontario Research Chair and has received (among others) the Lifetime Research Achievement award of the Canadian Cardiovascular Society; the Paul Wood Silver Medal of the British Cardiac Society; the European Society of Cardiology gold medal, the clinical Research Prize of the American Heart Association and the International Award and the Braunwald Lecture of the American College of Cardiology. He has been inducted into the Royal Society of Canada and the Canadian Medical Hall of Fame; been appointed as an Officer of the Order of Canada, and received the Canada Gairdner Wightman Award in 2014. He has received four honorary doctorates, and is among the top 20 most cited health researchers in history.
Salim Yusuf has published more than 1,000 articles in refereed journals, rising to the second most cited researcher in the world for 2011. He has mentored more than 120 scientists, several of whom are in leadership positions across the globe. He has been President of the World Heart Federation (2015-2016), where he initiated several programs (the Emerging Leaders program, road maps for CVD control and a course for training primary care practitioners in CVD prevention) aimed at halving the CVD burden globally within a generation. The World Heart Federation has recognized his contributions by naming the program the Salim Yusuf Emerging Leaders Programme.
He is a Distinguished University Professor of Medicine, and Executive Director of the Population Health Research Institute, McMaster University and Chief Scientist, Hamilton Health Sciences.
Koon Teo is a Professor of Medicine, Division of Cardiology, McMaster University, and provides senior leadership to PHRI’s direction and research studies. He has served as the acting director of the Division of Cardiology at McMaster University and Hamilton Health Sciences, and Chief of Cardiology, McMaster University Medical Centre. His wide range of work includes 16 book chapters, 356 articles and 280 abstracts featured in more than 15 medical journals worldwide.
He was the Canadian Principal Investigator for the COURAGE trial the results of which impact the practice of cardiology worldwide, and for the Canadian Institute for Health Research funded ongoing FAMILY study examining the origins of obesity and cardiometabolic risk factors in early childhood. He is also co-principal investigator of The International Polycap Study (TIPS).
Philip Joseph’s research interests include cardiovascular prevention, global health, heart failure, and cardiac imaging. He is the principal investigator for the PURE-AF substudy, and the SPECT-MINS study, an investigator in the PURE study, and the G-CHF registry. He is also the project officer for the TIPS-3 study. He has published more than 30 peer-reviewed scientific papers.
He is a fellow of the Royal College of Physicians and Surgeons of Canada, with certification in both internal medicine and cardiology. obtained his B.A.Sc at McMaster University in 2000, and his M.D. at Western University in 2004. His internal medicine (2004-2007) and cardiology (2007-2010) residencies were completed at the University of Ottawa. Subsequently, he completed additional clinical training in Nuclear Cardiology at McMaster University (2013), a M.Sc. in Health Research Methodology at McMaster (2010-13), and a post-doctoral research fellowship in PET imaging at Harvard University (2015).
Jackie Bosch started working with Salim Yusuf in 1993, before PHRI was formally created, as she was completing her Masters in Clinical Epidemiology, with the intent to learn how to do clinical trials so she could run trials in post-stroke rehabilitation. Most recently, she has been a co-investigator on large trials in primary and secondary prevention of cardiovascular disease and diabetes, as well as understanding the causes of functional decline as well as developing simple, internationally applicable interventions to improve post-stroke disability.
She is Assistant Dean of the Occupational Therapy program, School of Rehabilitation Sciences, McMaster University, and has received awards such as the (McMaster) President’s Award for Outstanding Service, and the PHRI Award for Outstanding Contributions to Global Collaborations. She has more than 65 peer-reviewed publications.
Sumathy Rangarajan has been Program Director, Global Health, since 2016, preceded by many years’ service at PHRI in other roles. She oversees the PURE study team, as well as the INVICTUS rheumatic AF treatment trial, the CANPWR pediatric weight management registry, and others.
She holds both a Bachelor of Science Degree and a Master of Science degree from Pune University in India.
Back To Top